Cai L, Jiang C, Zhang G, Fang H, et al. A multicenter, randomized, double-blinded, placebo-controlled, phase ? study evaluating the efficacy and safety of Xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 2024 Feb 15:ljae062. doi: 10.1093.
PMID: 38366639